Document:

<PAGE>

                                                                   EXHIBIT 10.42

March 6, 2000

Dr. Lawrence M. Souza, Ph.D.
417 Camino de Celeste
Thousand Oaks, CA  91360

Re:  Agreement Regarding Part-Time Special Assignment Position
     ---------------------------------------------------------

Dear Larry:

On behalf of Amgen Inc. ("Amgen"), I am pleased to confirm in this letter
agreement (the "Agreement") the terms and conditions under which you will
continue to be employed by Amgen from and after the date upon which you cease to
serve as Amgen's Senior Vice President of Research which will occur on March 15,
2000 (the "Effective Date").  You will remain in your current position and
receive all compensation and benefits of that position between now and the
Effective Date.  This Agreement also provides for the termination of your
employment with Amgen on or before July 31, 2002, as set forth below.

1.   POSITION AND DUTIES
     -------------------

     On the Effective Date, you will cease to be a regular full-time employee of
     Amgen and will resign from all offices you hold in Amgen and its
     subsidiaries, but you will continue to be employed by Amgen as an employee
     in a part-time special assignment position, at grade level 37, with the
     title of Special Advisor, Research reporting to Dr. Dennis Fenton, Senior
     Vice President, or his designee or successor. In connection with resigning
     your offices, you agree to execute and return to Amgen with this Agreement
     a signed original resignation letter (the "Resignation Letter") on your
     Amgen letterhead in the form provided in Appendix A to this Agreement.
     Appendix A is hereby incorporated into and made part of the Agreement by
     reference.

     As a Special Advisor, Research, you will assist Dennis, or his designee or
     successor, by providing technical and professional assessments of Amgen's
     current products and products which Amgen is in the process of developing
     as of the Effective Date and such other matters as you and Dennis, or his
     designee or successor, may mutually agree upon in the future.  You will be
     a member of the Research Department and, as such, Dennis or his successor
     or designee will assign these matters to you from time to time and you will
     provide Dennis, or his successor or designee with written or oral reports
     of your assessments.  Dennis or his successor or designee will evaluate
     your performance.

     Also, you will assist Steve Odre, Associate General Counsel, or his
     designee or successor, on intellectual property or other related legal
     matters or litigation.  This assistance may include, but shall not be
     limited to your meeting with Amgen attorneys, and testifying or otherwise
     appearing at depositions or court hearings scheduled as a result of any
     such litigation, including preparation for all the above.  Steve, or his
     designee or successor, will assign these matters from time to time and will
     evaluate your performance.
<PAGE>

Dr. Lawerence M. Souza, Ph.D.
March 6, 2000
Page 2

     Dennis and/or Steve, or their designees or successors (collectively, "Your
     Supervisor") will control and direct the manner in which you perform the
     services under this Agreement, including the details and means by which you
     provide your services.

     You will be an employee of Amgen for all purposes during the term of this
     Agreement and will not be an independent contractor.

     You will also be required to provide to Your Supervisor, upon their
     reasonable request, written or oral reports and/or copies of other written
     materials with regard to the foregoing.

     As we have discussed, the position of Special Advisor, Research is a part-
     time special assignment position in which you will be expected to work a
     minimum of ten (10) hours per month; however, you also agree that, to the
     extent that Your Supervisor requests, you will work up to twenty (20) hours
     per month.

     If requested by Your Supervisor, you agree to attend certain scientific
     meetings or programs related to your area of expertise so long as such
     meeting or program does not unreasonably interfere with your other
     activities.

     You will maintain a log showing the time you have spent performing the
     foregoing services and this log shall be deemed conclusive evidence of the
     time spent.  Amgen, at any time, may request a copy of your log and you
     agree to provide such a copy within a reasonable period of time after the
     request is made.  Furthermore, from time to time, your duties may require
     you to travel and attend meetings at various locations, including Amgen's
     Thousand Oaks facility, and you agree that no reasonable request by Your
     Supervisor for travel or attendance at meetings will be refused.  Your
     Supervisor will work with you in scheduling any such business trips or
     meetings so that they do not unreasonably interfere with your other
     activities and Amgen will reimburse you for your reasonable travel
     expenses.

     We have agreed that your part-time special assignment will continue until
     July 31, 2002, subject to extension as you and Amgen may agree in writing
     or to earlier termination by you or Amgen as set forth in Paragraph 8 of
     this Agreement.  As long as you are employed by Amgen, you will continue to
     be subject to Amgen's policies and procedures, including but not limited to
     those relating to the non-disclosure of proprietary and confidential
     information and you will continue to be subject to the Amgen Inc.
     Proprietary Information and Inventions Agreement, executed by you on or
     about July 27, 1981 (the "Proprietary Agreement") (which also contains
     obligations that survive the termination of your employment with Amgen).

     During the term of your part-time special assignment, except as set forth
     herein, you may not be employed by any person or company other than Amgen,
     without Amgen's prior approval.  You may, however, consult for companies
     outside the fields of biotechnology and/or pharmaceutics, or companies
     within these fields having less than 500 employees and no current
     contractual relationship with Amgen, provided that such consulting does not
     violate the Proprietary Agreement or interfere with your duties under this
     Agreement.  In addition, you may be self-employed, an independent
     contractor, a partner or a consultant in a venture
<PAGE>

Dr. Lawerence M. Souza, Ph.D.
March 6, 2000
Page 3

     fund, or a founding member of a biotechnology startup, provided these
     activities do not violate the Proprietary Agreement or interfere with your
     duties under this Agreement. Your engaging in the consulting and other
     activities described in the preceding two sentences shall not constitute a
     violation of paragraph D.2 of the Proprietary Agreement, provided that such
     consulting and other activities are not for any profit or non-profit
     institution which is competitive with or involves the businesses in which
     Amgen is engaged or its actual research and development, as of the
     Effective Date of this Agreement. You also agree that during the term of
     this Agreement you will not solicit for employment or affiliation,
     including as an independent contractor, any officer, director, or employee
     of Amgen or its subsidiaries.

2.   COMPENSATION AND BENEFITS
     -------------------------

     Following is a brief description of the compensation and benefits you will
     receive under this Agreement during your part-time special assignment.  The
     terms and conditions of all of your benefits are subject to the terms and
     conditions of each of the applicable plans, policies or arrangements, as
     they may be amended or terminated by Amgen from time to time.

     2.1  Compensation:  Your compensation will be $66,995 per month, subject to
          ------------
          applicable income tax and employment tax withholding requirements.  In
          addition, Amgen will reimburse you for any reasonable business
          expenses you incur in performing your duties, subject to Amgen's
          standard employee expense reimbursement policies.

     2.2  Administrative Support:  Amgen will provide you with an office and
          ----------------------
          secretarial assistance for any work that you perform while at Amgen's
          Thousand Oaks headquarters.  You will also be provided any office
          equipment and supplies you may need to perform your duties under this
          Agreement and you will have access to the services of Amgen's travel
          department.

     2.3  Management Incentive Plan:  You will not be eligible to participate in
          -------------------------
          Amgen's Management Incentive Plan (the "MIP") for any year after the
          1999 calendar year.

     2.4  Special Bonus for 2000 Calendar Year:  As part of the transition to
          ------------------------------------
          your part-time special assignment position, you will be entitled to a
          special bonus in the amount of 25% of your actual 1999 MIP award. This
          payment will be paid to you shortly after you receive your 1999 MIP
          payment.

     2.5  Employee Stock Purchase Plan:  You will be eligible to continue to
          ----------------------------
          participate in Amgen's Employee Stock Purchase Plan (the "ESPP") until
          the end of the current purchase period (March 31, 2000).  However, due
          to the fact that you will be working less than twenty (20) hours per
          week, you will not be eligible to participate in the ESPP after the
          current purchase period.

     2.6  Supplemental Retirement Plan:  As an employee in a part-time special
          ----------------------------
          assignment position, you will no longer be eligible to receive
          additional credits in your supplemental retirement plan account,
          although you will continue to maintain an account and receive earnings
          on the balance in your account until the termination of
<PAGE>

Dr. Lawerence M. Souza, Ph.D.
March 6, 2000
Page 4

          your employment.

     2.7  Retirement and Savings Plan:  Pursuant to Section 3.3 of the 401(k)
          ---------------------------
          Plan, employees that are eligible to participate in the 401(k) Plan
          are those that are classified as "regular full-time" or "regular part-
          time" employees. By signing below, you expressly acknowledge and agree
          that Amgen is not classifying you as a regular full-time or regular
          part-time employee and therefore, as of the Effective Date, you will
          not be eligible to make contributions or to have contributions made on
          your behalf to the 401(k) Plan. This letter qualifies as an agreement
          pursuant to Section 3.3(c)(2) of the 401(k) Plan. You will, however,
          be able to maintain your 401(k) account in the Amgen plan to the
          extent allowed by law.

     2.8  Change of Control Severance Plan:  You will continue to be eligible to
          --------------------------------
          participate in the Amgen Inc. Change of Control Severance Plan (the
          "CIC Plan").  However, on the Effective Date you will cease to be a
          Group I Participant and will become a Group II Participant in the CIC
          Plan by virtue of your ceasing to be a member of Amgen's Operating
          Committee. Notwithstanding the foregoing, in the event that the
          aggregate benefits provided for in this Agreement are greater than
          those provided in the CIC Plan upon a termination of employment for
          which you would be eligible to receive benefits under the terms and
          conditions of the CIC Plan, this Agreement, rather than the CIC Plan
          shall govern and control your rights upon a termination of employment;
          provided, that, in such event, and if applicable, you shall also
          receive the 280G tax gross-up benefit provided in Section 4.1(G) of
          the CIC Plan.

     2.9  Stock Options:
          -------------

          2.9.1  No New Grants:  As an employee in a part-time special
                 -------------
                 assignment position, you will not be eligible to receive
                 additional stock option grants after the Effective Date.

          2.9.2  Vesting During Special Assignment:  To the extent that you
                 ---------------------------------
                 continue in your part-time special assignment, you will be
                 eligible to continue to vest in all unvested options that have
                 previously been granted to you by Amgen on the dates and in the
                 manner provided in your stock option grant agreements and
                 applicable stock option plans. No stock options will vest
                 following the Termination Date as defined in Paragraph 8 of
                 this Agreement.

          2.9.3  Cooperation To Restructure:  As we have discussed, it is our
                 --------------------------
                 intention that your ability to continue to vest in and exercise
                 options while in your part-time special assignment position
                 will not result in any additional compensation charges to Amgen
                 in accordance with U.S. generally accepted accounting
                 principles. Accordingly, if at any time Amgen determines that
                 it is reasonably likely that Amgen will incur a compensation
                 charge as a result of your vesting or exercising options in
                 your part-time special assignment position then you agree that
                 you will use your reasonable best efforts to cooperate with
                 Amgen to restructure this Agreement and your position as Amgen
                 reasonably
<PAGE>

Dr. Lawerence M. Souza, Ph.D.
March 6, 2000
Page 5

                 determines is necessary for you to continue to be able to vest
                 and exercise your options without creating a compensation
                 charge to Amgen in accordance with U.S. generally accepted
                 accounting principles and without causing you to lose any of
                 the benefits of this Agreement. It is expressly understood that
                 Dr. Souza's "reasonable best efforts to cooperate with Amgen"
                 shall not require that he take or forbear from taking any
                 action that would result in any loss of value of the options.

          2.9.4  No Amendment to Stock Option Grant Agreements or Stock Option
                 -------------------------------------------------------------
                 Plans: Nothing in this Agreement shall be deemed to alter,
                 -----
                 amend, or otherwise modify the terms of your stock option grant
                 agreements or the terms of the applicable stock option plans.

     2.10 Medical, Dental, and Vision Insurance and COBRA: Your medical, dental,
          -----------------------------------------------
          and vision insurance coverage will terminate on the Effective Date. If
          after the Effective Date, you or your eligible dependents should elect
          to continue coverage under Amgen's group health plan(s) under the
          Consolidated Omnibus Budget Reconciliation Act ("COBRA") continuation
          rights, and you or your eligible dependents timely take the required
          steps to initiate such coverage, then Amgen will pay the cost of COBRA
          coverage for you and your eligible dependents until the earlier of
          September 14, 2001, or until you and/or your eligible dependents no
          longer qualify for COBRA continuation rights or, in the case of your
          dependents, the date on which such dependents cease to be eligible
          dependents under Amgen's group health plan(s), whichever occurs first.
          Generally, the period during which you and/or your eligible dependents
          will be eligible for COBRA benefits will be no more than eighteen (18)
          months from the Effective Date. However, if you and/or your eligible
          dependents qualify for COBRA benefits on or after September 14, 2001,
          then you and/or your eligible dependents will have the option of
          continuing coverage under Amgen's group health plan(s), under COBRA
          for the period for which you are entitled to receive COBRA benefits,
          provided that you and your eligible dependents continue to meet the
          qualification requirements under COBRA and under Amgen's group health
          plans and Amgen will pay the cost of such COBRA coverage for you and
          your eligible dependents until the earlier of July 31, 2002 or until
          you and/or your eligible dependents no longer qualify for COBRA
          continuation rights, or in the case of your dependents, the date on
          which such dependents cease to be eligible dependents under Amgen's
          group health plan(s) whichever shall occur first. If you obtain health
          insurance coverage for you and/or your COBRA eligible dependents for
          the period between March 14, 2001 and the Termination Date as defined
          in Paragraph 8 of this Agreement, then Amgen will reimburse you for
          the full cost of such insurance premiums. To receive reimbursement,
          submit copies of the health insurance premium invoices and other
          applicable information on a monthly basis to Amgen. For a complete
          description of the rights and responsibilities you and your eligible
          dependents have under COBRA, you must refer to the COBRA documents
          that will be sent to you by Amgen or its designee under separate
          cover.

     2.11 Basic Life Insurance:  Your Basic Life Insurance coverage will
          --------------------
          terminate on the
<PAGE>

Dr. Lawerence M. Souza, Ph.D.
March 6, 2000
Page 6

          Effective Date. If you are interested in converting this insurance to
          an individual policy, please contact Jean Ellis at Aetna (860) 273-
          7252 within thirty (30) days after the Effective Date.

     2.12 Long-Term Disability Insurance:  Your Long-Term Disability Plan
          ------------------------------
          coverage will terminate on the Effective Date and there is no
          conversion policy or plan available for this coverage.

     2.13 Amgen Foundation Matching Funds:  During the term of your special
          -------------------------------
          assignment, contributions you make to qualified organizations will
          continue to be eligible for matching funds from the Amgen Foundation,
          subject to the same terms, conditions, and limitations that apply to
          contributions made by regular, full-time employees of Amgen.

     2.14 Other Benefits:  As an employee in a part-time special assignment
          --------------
          position, you will not be eligible to participate in the following
          Amgen benefit plans and programs as well as any other benefits not
          specifically listed in this letter: Dependent Care Assistance Program;
          Medical Flexible Spending Account; Voluntary and Dependent Life
          Insurance coverage, Accidental Death and Dismemberment benefit; use of
          Amgen Fitness Center facilities; use of Amgen Child Care Center
          facilities; personal illness; vacation/optional holiday pay; family
          illness/personal time; bereavement leave or holidays. Your accrued and
          unused vacation hours and optional holiday pay will be paid to you on
          the next regularly scheduled payroll date following the Effective
          Date.

3.   TRANSFER OF COMPANY PROPERTY
     ----------------------------

     Except as provided in the remainder of this Subparagraph, you promise that
     on or before the Termination Date, as defined in Paragraph 8 of this
     Agreement, you will return to Amgen all files, memoranda, documents,
     records, copies of the foregoing, credit cards, keys, and any other Amgen
     property in your possession or under your control.  As an employee in a
     part-time special assignment position, you will continue to have access to
     and use of the following items: Compaq Deskpro computer, Mitsubishi Diamond
     Pro 9TTXM monitor, Compaq keyboard and mouse, Kodak audioviewer projector,
     portable lightbox, Panasonic pencil sharpener, and 8 slide carousels
     (without slides), that Amgen previously provided to you.  As of the
     termination of your employment with Amgen, you will be entitled to retain
     the equipment referenced in the preceding sentence provided that you take
     the steps necessary to ensure that all of Amgen's proprietary information
     is deleted from the computer by Amgen's computer services department as of
     the Termination Date as defined in Paragraph 8 of this Agreement.

4.   OFFICERS AND DIRECTORS INSURANCE
     --------------------------------

     During your part-time special assignment and for four (4) years following
     the Termination Date, you will be covered by such officers and directors
     insurance coverage that Amgen provides to its senior executive officers at
     your salary grade level during that time period.  In
<PAGE>

Dr. Lawerence M. Souza, Ph.D.
March 6, 2000
Page 7

     addition, Amgen shall indemnify and hold you harmless both during and after
     the entire term of your employment (including your service hereunder) to
     the fullest extent permitted by law with regards to actions or inactions in
     relation to your duties performed at Amgen, both before and after the date
     of this Agreement. Furthermore, you will be entitled to reimbursement of
     expenses incurred in accordance with your rights under California Labor
     Code Section 2802.

5.   LEGAL FEE AND FINANCIAL/TAX CONSULTING REIMBURSEMENT
     ----------------------------------------------------

     Amgen will reimburse you for the legal expenses reasonably incurred by you
     in connection with the review of this Agreement up to a maximum amount of
     $10,000.  Amgen will also reimburse you for financial and/or tax counseling
     expenses that you reasonably incur, up to a maximum amount of $3,000 per
     year, for each year of this Agreement.

6.   REFERENCE
     ---------

     Amgen will provide you with a positive written factual reference.  Gordon
     M. Binder should be listed as your work reference.  You agree to confer
     with me on the form and nature of the reference to be provided to third
     parties concerning the work that you have performed at Amgen.  If, by sixty
     (60) days after the Effective Date, you are unable to reach agreement with
     me on the written reference to be provided, then Amgen's only obligation
     will be to respond to inquiries by confirming to third parties the dates of
     your  employment at Amgen and the last position you held as an Amgen
     employee.

7.   RELOCATION
     ----------

     If you decide to relocate outside of the fifty (50) mile radius of your
     Residence (as defined below) during the period of your part-time special
     assignment or immediately at the termination thereof for any reason other
     than for a Stated Reason, as defined below, and sell your current, local,
     primary residence located in Thousand Oaks, California (the "Residence") so
     that the sale escrow closes no later than July 31, 2002, then Amgen will
     provide you with the following:

     7.1  If your new employer, if any, provides for part of the following
          expenses, then Amgen would pay normal and customary amounts beyond
          those which such new employer paid, up to the amounts that Amgen would
          normally pay, as of the date your employment with Amgen terminated, to
          newly hired Amgen employees in your job: normal and customary costs
          for the packing, shipping, delivery, storage (for up to ninety (90)
          days) and unpacking of your common household goods and furnishings.

     7.2  If you shall sell your Residence so that the close of escrow on the
          sale occurs prior to July 31, 2002, then in such event, Amgen will
          reimburse you for those normal and non-recurring customary sales costs
          associated with the sale of such residence, subject to the following
          terms and conditions:
<PAGE>

Dr. Lawerence M. Souza, Ph.D.
March 6, 2000
Page 8

          7.2.1  Amgen's obligation will be limited to that amount which, as of
                 the day immediately prior to the date of this Agreement, Amgen
                 would pay to reimburse other employees of your then salary
                 grade level;

          7.2.2  to the extent that your new employer, if any, reimburses you
                 for, or pays any of, such non-recurring customary sales costs,
                 then Amgen will only reimburse you for that portion of the non-
                 recurring customary sales costs that exceed the amount paid for
                 by such new employer; and

          7.2.3  you provide all documentation requested by Amgen in connection
                 with this Subparagraph 7.2, upon the request of Amgen.

     7.3  If you meet the above conditions and so elect, Amgen will grant you
          the opportunity to place your Residence in the "Amgen Marketing
          Assistance and Homesale Program" (the "Program"). For a description of
          the Program, please contact Christine Swinburne of the Amgen Human
          Resources Department. In order to participate in the Program, you must
          notify Ms. Swinburne in writing, of your election to participate in
          the Program no later than January 19, 2002, in order to complete the
          home sale process by July 19, 2002. In order for Amgen to provide you
          with the assistance provided for in this Subparagraph 7.3 in
          connection with the sale of your Residence, you must give Amgen
          control over the disposition of the property, must provide such
          documentation as Amgen may request and must cooperate with Amgen in
          the sale of the Residence.

8.   EARLY TERMINATION OF SPECIAL ASSIGNMENT
     ---------------------------------------

     We have agreed that you will continue in your part-time special assignment
     position until July 31, 2002, at which time your employment with Amgen will
     terminate, provided however, that Amgen may terminate your employment prior
     to July 31, 2002 and you may terminate your employment prior to July 31,
     2002 upon thirty (30) days prior written notice to Amgen.

     For purposes of this Paragraph 8, a "Stated Reason" means (i) your
     conviction of a felony, (ii) the engaging by you in conduct that
     constitutes willful gross neglect or willful gross misconduct in carrying
     out your duties set forth in Paragraph 1 of this Agreement, resulting, in
     either case, in material economic harm to Amgen, unless you believed in
     good faith that such conduct was in, or not contrary to, the best interests
     of Amgen; or (iii) your material breach of any of the terms of this
     Agreement.  For purposes hereof, no act, or failure to act, on your part
     shall be deemed "willful" unless done, or omitted to be done, by you not in
     good faith.  For purposes of this Paragraph 8, a "Covered Breach" means a
     breach by Amgen of its obligations under this Agreement in the following
     manner only (i) any reduction in your salary or benefits provided for in
     this Agreement or (ii) the assignment of duties to you that are
     inconsistent with, or greater in scope than, those set forth in Paragraph 1
     of this Agreement or (iii) a reduction in your title or position or (iv) a
     failure by Amgen to have any successor expressly assume this Agreement in
     accordance with Paragraph 17 of this Agreement.  In order for an event
     described in the preceding sentence to qualify as a Covered
<PAGE>

Dr. Lawerence M. Souza, Ph.D.
March 6, 2000
Page 9

     Breach, you must give written notice of the event to Amgen and Amgen must
     fail to cure the event within 30 days of receipt of that written notice.

     In the event your employment is terminated by Amgen for a Stated Reason or
     if you terminate your employment for any reason other than a Covered Breach
     then your payments and benefits from Amgen under this Agreement, including
     but not limited to the vesting of your stock options, will cease as of the
     effective date of the termination of your employment.

     In the event your employment is terminated by Amgen not for a Stated Reason
     or if you terminate your employment for a Covered Breach, then (i) you
     shall be paid in a cash lump-sum all of the remaining cash payments due to
     you under this Agreement from the date of your termination through July 31,
     2002, (ii) you shall continue to be provided the benefits set forth in
     Paragraph 2.10 of this Agreement through July 31, 2002 and (iii) Amgen
     shall take the necessary corporate action to accelerate the vesting of all
     of your outstanding and then unvested stock options so that they shall vest
     and become immediately exercisable in full as of the Termination Date; such
     stock options, as so accelerated shall be exercisable as provided in your
     stock option grant agreements and applicable stock option plans.

     The date of the termination of your employment for any of the foregoing
     reasons, or upon your death, is hereinafter referred to as the "Termination
     Date."

9.   DEATH
     -----

     In the event of the termination of your employment hereunder by reason of
     your death prior to July 31, 2002, all of the remaining payments pursuant
     to Paragraph 2.1 of this Agreement will be payable to the beneficiary or
     beneficiaries that you designate in writing to Amgen.  Your other remaining
     benefits will be treated according to their specific terms concerning such
     death.  For purposes of Paragraph 10(a) of the Amgen Inc. Amended and
     Restated 1991 Equity Incentive Plan, your employment with Amgen shall be
     deemed to have commenced in 1981, when you first became an employee at
     Amgen.

10.  RELEASE
     -------

     In exchange for consideration provided to you under this Agreement, you
     hereby agree to execute and be bound by the General Release attached hereto
     as Appendix B (the "General Release") and to return the executed Agreement,
     together with the executed General Release, to me on or before March 10,
     2000.  The General Release is hereby incorporated into and made part of the
     Agreement by this reference.

11.  INTERPRETATION
     --------------

     This Agreement, the Resignation Letter attached hereto as Appendix A, and
     the General Release attached hereto as Appendix B shall be construed as a
     whole according to their fair meaning, and not strictly for or against any
     of the parties.  Unless the context indicates otherwise, the term "or"
     shall be deemed to include the term "and" and the singular or plural number
     shall be deemed to include the other.  Paragraph headings used in this
     Agreement
<PAGE>

Dr. Lawerence M. Souza, Ph.D.
March 6, 2000
Page 10

     and the General Release are intended solely for convenience of reference
     and shall not be used in the interpretation of any of this Agreement or the
     General Release.

12.  NOTICES
     -------

     For the purposes of this Agreement, notices, demands and all other
     communications provided for in this Agreement shall be in writing and shall
     be deemed to have been duly given when delivered either personally or by
     United States certified or registered mail, return receipt requested,
     postage prepaid, addressed, if to you, to the last address on file with
     Amgen and if to Amgen, to its executive offices or to such other address as
     any party may have furnished to the others in writing in accordance
     herewith, except that notices of change of address shall be effective only
     upon receipt.

13.  LEGAL FEES; ARBITRATION
     -----------------------

     13.1 Agreement to Arbitrate:  Any dispute (an "Arbitrable Dispute") arising
          ----------------------
          between the parties, including but not limited to those concerning the
          formation, validity, interpretation, effect, or alleged violations of
          this Agreement or the General Release, must be submitted to binding
          arbitration for resolution in Los Angeles, California in accordance
          with the rules and procedures of the Employment Dispute Resolution
          Rules of the American Arbitration Association then in effect. The
          decision of the arbitrator shall be final and binding on both parties,
          and any court of competent jurisdiction may enter judgment upon the
          award.  Except for an action taken outside of arbitration pursuant to
          Subparagraph 13.4 of this Agreement, should either party pursue any
          other legal or administrative action against the other, the responding
          party shall be entitled to the return of any payments that party made
          under the Agreement and shall be entitled to recover all costs,
          expenses and attorneys' fees the responding party incurs as a result
          of such action.  The arbitrator may not modify or change this
          Agreement or the General Release in any way.

     13.2 Costs of Arbitration:  Each party shall pay the fees of their
          --------------------
          respective attorneys, the expenses of their witnesses and any other
          expenses connected with the arbitration, but all other costs of the
          arbitration, including the fees of the arbitrator, cost of any record
          or transcript of the arbitration, administrative fees and other fees
          and costs shall be paid in equal shares by you and Amgen. The party
          losing the arbitration shall reimburse the party who prevailed for all
          fees and expenses the prevailing party paid pursuant to the preceding
          sentence, and (where a prevailing-party attorney's fees provision
          exists) shall also reimburse the prevailing party for attorney's fees
          paid.

     13.3 Exclusive Remedy:  Arbitration in this manner shall be the exclusive
          ----------------
          remedy for any Arbitrable Dispute. The arbitrator's decision or award
          shall be fully enforceable and subject to an entry of judgment by a
          court of competent jurisdiction. Except for an action taken outside of
          arbitration pursuant to Subparagraph 13.4 of this Agreement, should
          you or Amgen, without the consent of the other party, attempt to
          resolve an Arbitrable Dispute by any method other than arbitration
          pursuant to this Paragraph
<PAGE>

Dr. Lawerence M. Souza, Ph.D.
March 6, 2000
Page 11

          13, the responding party shall be entitled to recover from the
          initiating party all damages, expenses and attorneys' fees incurred as
          a result.

     13.4 Sole Exception:  Notwithstanding the foregoing, a dispute relating to
          --------------
          the alleged use or disclosure of information which is prohibited by
          the Proprietary Agreement, and/or the criticism, denigration or
          disparagement of Amgen, any other Amgen Releasee, as defined in
          Subparagraph 1.1 of the General Release, or any of Amgen's products,
          processes, experiments, policies, practices, standards of business
          conduct, or areas or techniques of research may be resolved through a
          means other than arbitration, at Amgen's sole option.

14.  GOVERNING LAW
     -------------

     This Agreement is governed by, and is to be construed and enforced in
     accordance with, the laws of the State of California, without regard to
     principles of conflicts of laws.

15.  TAXES
     -----

     You acknowledge and agree that all payments made pursuant to this Agreement
     shall be made less applicable tax withholdings and/or other withholdings as
     required by law.  You acknowledge and agree that you, and not Amgen, shall
     be solely responsible for any taxes imposed upon you as a result of the
     payments and benefits you receive under the Agreement with the sole
     exception of the potential 280G tax gross-up as provided in Subparagraph
     2.8 of this Agreement.  This paragraph shall not be construed to require
     you to pay Amgen's portion of any employment tax withholding, such as
     Amgen's portion of FICA or FUTA.

16.  NO ASSIGNMENT OR DELEGATION
     ---------------------------

     Amgen has selected you for this part-time special assignment because it has
     judged that your unique experience and skills are those Amgen required for
     the job.  Accordingly, you may not assign or delegate any of your duties or
     responsibilities under this Agreement.

17.  SUCCESSORS; BINDING AGREEMENT
     -----------------------------

     17.1 Amgen's Successors:  No rights or obligations of Amgen under this
          ------------------
          Agreement may be assigned or transferred except that Amgen will
          require any successor (whether direct or indirect, by purchase,
          merger, consolidation or otherwise) to all or substantially all of the
          business and/or assets of Amgen to expressly assume and agree to
          perform this Agreement in the same manner and to the same extent that
          Amgen would be required to perform it if no such succession had taken
          place. As used in this Agreement, "Amgen" shall mean Amgen as herein
          before defined and any successor to its business and/or assets (by
          merger, purchase or otherwise) which executes and delivers the
          agreement provided for in this Paragraph 17 or which otherwise becomes
          bound by all the terms and provisions of this Agreement by operation
          of law.
<PAGE>

Dr. Lawerence M. Souza, Ph.D.
March 6, 2000
Page 12

     17.2 Your Successors: No rights or obligations of you under this Agreement
          ---------------
          may be assigned or transferred by you other than your rights to
          payments or benefits hereunder, which may be transferred only by will
          or the laws of descent and distribution. Upon your death, this
          Agreement and all rights of you hereunder shall inure to the benefit
          of and be enforceable by your beneficiary or beneficiaries, personal
          or legal representatives, or estate, to the extent any such person
          succeeds to your interests under this Agreement. You shall be entitled
          to select and change a beneficiary or beneficiaries to receive any
          benefit or compensation payable hereunder following your death by
          giving Amgen written notice thereof. In the event of your death or a
          judicial determination of your incompetence, reference in this
          Agreement to you shall be deemed, where appropriate, to refer to your
          beneficiary(ies), estate or other legal representative(s). If your
          should die following your Termination Date while any amounts would
          still be payable to you hereunder if you had continued to live, all
          such amounts unless otherwise provided herein shall be paid in
          accordance with the terms of this Agreement to such person or persons
          so appointed in writing by you, or otherwise to your legal
          representatives or estate.

18.  ENTIRE AGREEMENT
     ----------------

     The Proprietary Agreement, your stock option agreements, this Agreement,
     the Resignation Letter attached hereto as Appendix A, and the General
     Release attached hereto as Appendix B constitute the entire agreement,
     arrangement and understanding between you and Amgen; they may not be
     modified or canceled in any manner except by a writing signed by both you
     and Amgen.  This Agreement and the General Release supersede any prior or
     contemporaneous agreement, arrangement or understanding on this subject
     matter.  By executing this Agreement, the Resignation Letter, and the
     General Release below, you expressly acknowledge the termination of any
     such prior agreement, arrangement or understanding.  Also, by executing
     this Agreement, the Resignation Letter, and the General Release, you affirm
     that no one has made any written or verbal statement that contradicts the
     provisions of this Agreement, the Resignation Letter, or the General
     Release.

                                    Sincerely yours,

                                    /s/ Gordon M. Binder
                                    ------------------------------------
                                    Amgen Inc.
                                    By:  Gordon M. Binder
                                    Chief Executive Officer and Chairman

     Acknowledged and Agreed:

     /s/ Lawrence M. Souza
     ----------------------------
     Dr. Lawrence M. Souza, Ph.D.

     Dated:  3/8/00
            ---------------------
<PAGE>

                                  APPENDIX A
<PAGE>

                                  RESIGNATION
                                  -----------

The undersigned hereby resigns, effective March 15, 2000, as an officer and/or
director of Amgen Inc. and any and all Amgen affiliates and subsidiary entities.

                              /s/ Lawrence M. Souza
                              ----------------------------
                              Dr. Lawrence M. Souza, Ph.D.
<PAGE>

                                  APPENDIX B

                            MUTUAL GENERAL RELEASE

     By signing below, Amgen Inc. ("Amgen" or the "Company") and you, Dr.
Lawrence M. Souza, Ph.D., agree to all of the terms and conditions set forth in
this Mutual General Release, which resolves all issues between you and the
Company including, but not limited to, those related to your employment with the
Company, and the termination thereof.

1.   COMPLETE RELEASE
     ----------------

     1.1  Release:  In exchange for consideration provided to you and the
          -------
          Company under the Agreement, the receipt of which and adequacy thereof
          you and the Company hereby acknowledge, you irrevocably and
          unconditionally release all the claims described in Subparagraph 1.2
          of this General Release that you may have against the following
          persons or entities (collectively the "Amgen Releasees"): Amgen, all
          related or affiliated companies and all of Amgen's or such related or
          affiliated companies' predecessors, successors, and assigns; and, with
          respect to each such entity, all of its past and present employees,
          officers, directors, stockholders, owners, representatives, assigns,
          attorneys, agents, insurers, employee benefit programs (and the
          trustees, administrators, fiduciaries and insurers of such programs)
          and any other persons acting by, through, under or in concert with any
          of the persons or entities listed in this Subparagraph and each of
          them; and the Company irrevocably and unconditionally releases all the
          claims described in Subparagraph 1.2 of this General Release that the
          Company may have against you, your employees, agents, attorneys,
          representatives, successors, and assigns, past and present and each of
          them.

     1.2  Claims Released:  Except as provided in Subparagraph 1.4 of this
          ---------------
          General Release, the claims released include all claims of whatever
          nature, whether known or unknown, suspected or unsuspected, by either
          you or Amgen which you or Amgen now owns or holds or has at any time
          previously held, or (with the sole exception of claims covered by
          Subparagraph 1.4 of this General Release) ever in the future may hold
          including statutory claims arising under the employment discrimination
          laws. In particular, you acknowledge and agree that by signing the
          Agreement and this General Release, in addition to the matters
          discussed above, you are waiving and releasing any and all claims,
          charges, or rights you may have under the Age Discrimination In
          Employment Act of 1967, as amended (the "ADEA"), that this waiver and
          release is knowing and voluntary, and that the consideration given for
          this waiver and release is in addition to anything of value to which
          you were already entitled as an employee of Amgen. You further
          acknowledge that you have been advised that: (a) you should consult
          with an attorney (at your own expense, subject to your right to
          reimbursement as set forth in Paragraph 5 of the Agreement) prior to
          executing the Agreement and this General Release; (b) you have at
          least twenty-one (21) days in which to consider the Agreement and this
          General Release (although you may choose to execute the Agreement and
          this General Release earlier and waive all of or part of the 21-day
          period); (c) the Agreement and this General Release do not

                                                                             B-1
<PAGE>

          waive or release any rights or claims you may have under the ADEA
          which may arise after you execute the Agreement and this General
          Release; (d) you have seven (7) days following execution of the
          Agreement and this General Release to revoke your consent to the
          Agreement and this General Release (to be effective, any revocation
          must be actually received in writing by me by 5:30 p.m. on the seventh
          day); and (e) the Agreement and this General Release shall not be
          effective until the seven (7) day revocation period has expired. In
          the event that you exercise this right to revoke this General Release,
          you and Amgen agree that the Agreement (including without limitation
          the Resignation Letter attached to the Agreement as Appendix A) will
          be simultaneously revoked. You also acknowledge and agree that you
          were first given a copy of the Agreement and this General Release on
          January 26, 2000, that you have been given the opportunity to consult
          with whomever you wish regarding the Agreement and this General
          Release and that you have entered into the Agreement and this General
          Release voluntarily and with full knowledge of its final and binding
          effect.

     1.3  Release Extends to Both Known and Unknown Claims: This General Release
          ------------------------------------------------
          covers both claims that you and/or Amgen know about and those you
          and/or Amgen do not know about.  You understand the significance of
          this release of unknown claims and this waiver of statutory protection
          against a release of unknown claims by both you and Amgen.  You and
          Amgen each expressly waive all rights afforded by any statute which
          limits the effect of a release with respect to unknown claims.  You
          and Amgen each expressly waive the protection of (S) 1542 of the Civil
          Code of the State of California.

     1.4  Claims Not Released:  This General Release does not release your right
          -------------------
          or the Company's right to enforce the Agreement.

2.   YOUR PROMISES
     -------------

     In addition to the release of claims provided for in Paragraph 1 of this
     General Release, you also agree to the following:

     2.1  No Future Employment:  You understand that, as provided in Paragraph 8
          --------------------
          of the Agreement, your employment with Amgen and all related or
          affiliated companies will terminate forever on the Termination Date
          and you promise never to seek employment with Amgen or its related or
          affiliated companies in the future, except that if you are employed by
          a company that Amgen acquires in the future, you will not be
          terminated solely by virtue of this paragraph.  If your employment is
          not terminated by Amgen for a Stated Reason, Amgen shall treat this
          termination as a resignation on its records.  You acknowledge and
          agree that the Agreement, together with this General Release,
          contemplates your termination from Amgen on the Termination Date, and
          that the release in Paragraph 1 of this General Release shall cover
          your entire employment with Amgen and the termination of that
          employment.

                                                                             B-2
<PAGE>

     2.2  You are Not to Harm Amgen:  You agree not to knowingly and willfully
          -------------------------
          criticize, denigrate or otherwise disparage Amgen, any other Amgen
          Releasee, or any of Amgen's products, processes, experiments,
          policies, practices, standards of business conduct, or areas or
          techniques of research to the extent that such conduct causes
          demonstrable injury to Amgen; provided, however, that nothing in this
          General Release shall prohibit you from complying with any lawful
          subpoena or court order.

     2.3  No Knowledge of Violations:  You represent that you are not aware of
          --------------------------
          any facts that would (a) establish, (b) tend to establish, or (c) in
          any way support an allegation of a violation by Amgen of the federal
          False Claims Act (or any similar state or federal qui tam statute).
                                                            --- ---

3.   CONSEQUENCES OF YOUR VIOLATION OF YOUR PROMISES
     -----------------------------------------------

     3.1  General Consequences:  If you break any of the promises made in the
          --------------------
          Agreement or this General Release, for example, by filing or
          prosecuting a lawsuit based on claims that you have released, or if
          any representation made by you in this General Release was false when
          made, you (a) shall forfeit all right to future benefits under the
          Agreement; (b) must repay all benefits previously received, other than
          the monthly compensation paid to you under Paragraph 2.1 of the
          Agreement, upon Amgen's demand; and (c) must pay reasonable attorneys'
          fees and all other costs incurred as a result of your breach or false
          representation, such as the cost of defending any suit brought with
          respect to a released claim by you or other owner of a released claim.
          It is agreed that your breach of Subparagraph 2.2 of this General
          Release will not be covered by this Paragraph 3.1 unless you are given
          written notice by the Company specifying your breach of Subparagraph
          2.2 and you fail to cure such a breach within 14 days of receipt of
          such notice.

          In addition, in order to ensure that you have complied fully with your
          obligations under Paragraph 2.3 of this General Release, you hereby
          covenant and agree that to the full extent permitted by law, you
          hereby waive and release any and all rights or claims you may have to
          any personal claim for proceeds or awards that you may be entitled to
          under any qui tam proceeding brought against Amgen.  You further agree
                    --- ---
          that you shall deliver any such money, proceeds, or awards to the U.S.
          government.

     3.2  Injunctive Relief:  You further agree that Amgen would be irreparably
          -----------------
          harmed by any use or disclosure of information that is prohibited by
          the Amgen Inc. Proprietary Information and Inventions Agreement,
          executed by you on or about July 27, 1981 (the "Proprietary
          Agreement") (which contains obligations that survive the termination
          of your employment with Amgen), and that Amgen shall be entitled to an
          injunction prohibiting you from committing any such violation.

     3.3  Challenges to Validity:  Should you attempt to challenge the formation
          ----------------------
          or enforceability of the Agreement and/or this General Release, you
          shall initially tender, by certified check delivered to Amgen, all
          amounts received pursuant to the Agreement, other than the monthly
          compensation paid to you under Paragraph 2.1 of

                                                                             B-3
<PAGE>

          the Agreement, plus interest at the legal rate and invite Amgen to
          cancel the Agreement. In the event Amgen accepts this offer, the
          Agreement shall be canceled. In the event Amgen does not accept this
          offer, Amgen shall so notify you and the amount tendered by you shall
          be placed in an interest-bearing account pending a determination of
          the enforceability of the Agreement and/or this General Release. If
          the Agreement and this General Release are determined to be
          enforceable, the amount in the account shall be repaid to you; if the
          Agreement and/or this General Release are determined not to be
          enforceable, the amount in the account shall be retained by Amgen or
          its designee.

4.   VOLUNTARILY ENTERING AGREEMENT
     ------------------------------

     You acknowledge that you (a) have had a sufficient period to consider and
     review the Agreement and this General Release before signing them; (b) have
     carefully read the Agreement and this General Release; and (c) fully
     understand the Agreement and this General Release and are entering into
     them voluntarily.

5.   SEVERABILITY
     ------------

     The provisions of this General Release are severable. If any one or more of
     the provisions contained herein, or the application thereof in any
     circumstance, is held invalid, illegal or unenforceable in any respect and
     for any reason, the validity, legality and enforceability of any such
     provision in every other respect and of the remaining provisions hereof
     shall not be affected or impaired in any way, it being intended that all of
     the parties' rights and privileges arising hereunder shall be enforceable
     to the fullest extent permitted by law.

PLEASE READ THIS GENERAL RELEASE CAREFULLY.  IT CONTAINS A RELEASE OF ALL KNOWN
AND UNKNOWN CLAIMS.

Executed at Thousand Oaks, California this 8th day of March, 2000.
            -------------                  ---        -----

/s/ Lawrence M. Souza
----------------------------
Dr. Lawrence M. Souza, Ph.D.

Executed at Thousand Oaks, California this 6th day of March, 2000.
                                           ---        -----

/s/ Gordon M. Binder
------------------------------------
Amgen Inc.
By:  Gordon M. Binder
Chief Executive Officer and Chairman

                                                                             B-4<PAGE>

                                                                   EXHIBIT 10.19

                         NON-RECOURSE PROMISSORY NOTE
                         ----------------------------

$500,000                                              San Francisco, California
                                                                October 6, 1999

     For value received, the undersigned promises to pay Aeneid Corporation, a
California corporation (the "Company"), at its principal office the principal
                             -------
sum of $500,000, together with interest on the sum of the outstanding principal
balance, plus accrued but unpaid interest, at the rate of 5.41% per annum,
compounded monthly. Such principal and interest shall be due and payable on
October 6, 2002.

     Principal and interest are payable in lawful money of the United States of
America. AMOUNTS DUE UNDER THIS NOTE MAY BE PREPAID AT ANY TIME WITHOUT INTEREST
OR PENALTY.

     Should suit be commenced to collect any sums due under this Note, such sum
as the Court may deem reasonable shall be added hereto as attorneys' fees. The
makers and endorsers have severally waived presentment for payment, protest,
notice of protest, and notice of nonpayment of this Note.

     This Note, which is non-recourse, is secured by a pledge of certain shares
of Common Stock of the Company owned by the undersigned and is subject to the
terms of a Pledge and Security Agreement between the undersigned and the Company
of even date herewith.

     THIS NOTE IS NON-RECOURSE TO THE UNDERSIGNED. The Company shall look solely
to any collateral securing this Note for payment of any unpaid amounts due under
this Note, whether or not the value of such collateral is sufficient to
liquidate the entire amount due. The Company shall have no claim against the
undersigned for payment of any amount due under this Note other than to the
extent of the interest of the undersigned in the collateral securing this Note
in accordance with the aforementioned Pledge and Security Agreement.

     In the event that any one or more provisions of this Note shall be held to
be illegal, invalid or otherwise unenforceable, the same shall not affect any
other provision of this Note, and the remaining provisions of this Note shall
remain in full force and effect.

     This Note shall be governed by, and construed in accordance with, the laws
of the State of California without regard to conflicts of laws principles.

                                    /s/ David Putterman
                                    ---------------------------
                                    Daniel Putterman

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00008-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00008-of-00352.parquet"}]]